🇺🇸 FDA
Patent

US 11446238

Injectable dendrimer hydrogel nanoparticles

granted A61KA61K31/43A61K47/595

Quick answer

US patent 11446238 (Injectable dendrimer hydrogel nanoparticles) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K31/43, A61K47/595, A61K47/6903, A61K9/0019